Compare Danaher Corporation (DHR) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs SOLAI Limited — how do they compare? Danaher Corporation trades at $219.41 (market cap $152.87B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Danaher Corporation is far larger — about 173.7× SOLAI Limited's market cap, and Danaher Corporation pays a 0.74% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and SOLAI Limited for 40 Days on average.
| DHR | SLAI | |
|---|---|---|
Market Cap | $152.87B | $880.09M |
Volume | 5,228,698 | 122,720 |
Sector | Health | Technology |
52-Week High | $242.05 | $21.63 |
52-Week Low | $161.91 | $2.74 |
Typical Hold Time | 69 Days | 40 Days |
Enterprise Value | $175.08B | $879.73M |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
SLAI trades at $3.72 with no recent price movement. The technical picture is bullish based on moving averages and oscillators, though the stock faces delisting proceedings from the NYSE. Fundamentally, the company shows severe distress with negative gross and net income margins, high revenue decline, and substantial losses despite a low P/B ratio. Recent news highlights governance changes amid exchange compliance issues.
The outlook is highly risky due to financial instability and delisting threat. Investment opportunity exists only for speculative traders betting on a turnaround, given the low valuation multiple. Key risks include continued cash burn, inability to achieve profitability, and loss of major exchange listing impacting liquidity and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
